TXNDC5 and liver cancer: Inhibiting TXNDC5 expression in cervical cancer [21], castration-resistant prostate cancer [29], RCC [34], gastric cancer [25], laryngeal squamous cell carcinoma (LSCC) [43], pancreatic cancer [38], and liver cancer [35] can promote cell apoptosis and inhibit cell proliferation and migration.